Immunotyping of human immunodeficiency virus type 1 (HIV): An approach to immunologic classification of HIV

Journal of Virology

Volumn 73, Issue 5, 1999, Pages 4042-4051

  Zolla Pazner, Susan ^a,b   Gorny, Miroslaw K ^b   Nyambi, Phillipe N ^b   VanCott, Thomas C ^c   Nádas, Arthur ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c 3Henry M Jackson Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLUSTER ANALYSIS; EPITOPE MAPPING; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOPHENOTYPING; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; VIRUS CHARACTERIZATION; VIRUS CLASSIFICATION; VIRUS NEUTRALIZATION;

EID: 0032943087     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.5.4042-4051.1999     Document Type: Article

References (56)

1. Altman, L. K. 4 June 1998. FDA authorizes first full testing for HIV vaccine, p. A1. New York Times, New York, N.Y.
2. Andries, K., B. Dewindt, J. Snoeks, L. Wouters, J. Moereels, P. J. Lewi, and P. A. J. Janssen. 1990. Two groups of rhinoviruses revealed by a panel of antiviral compounds present sequence divergence and differential pathogen-city. J. Virol. 64:1117-1123.
3. Baillou, A., D. Brand, F. Denis, S. M'Boup, R. Chout, A. Goudeau, and F. Barin. 1993. High antigenic cross-reactivity of the V3 consensus sequences of HIV-1 gp120. AIDS Res. Hum. Retroviruses 9:1209-1215.
4. Barin, F., Y. Lahbabi, L. Buzelay, B. LeJeune, A. Baillou-Beaufils, F. Denis, C. Mathiot, S. M'Boup, V. Vithayasai, U. Dietrich, and A. Goudeau. 1996. Diversity of antibody binding to V3 peptides representing consensus sequences of HIV type 1 genotypes A to E: an approach for HIV type 1 serological subtyping. AIDS Res. Hum. Retroviruses 12:1279-1289.
5. Bodmer, J., P. Pickbourne, W. Bodmer, R. Batchelor, P. Dewar, H. Dick, C. Entwistle, H. Festenstein, K. Gelsthorpe, V. Joysey, P. Mackintosh, S. Lawler, P. Morris, G. D. Pegrum, R. Harris, and M. Taylor. 1976. Serological identification of Ia antigens: report of a British region Ia workshop. Tissue Antigens 8:359-371.
6. Burton, D. R., J. Pyati, R. Koduri, S. J. Sharp, G. B. Thornton, P. W. H. I. Parren, L. S. W. Sawyer, R. M. Hendry, N. Dunlop, P. L. Nara, M. Lamacchia, E. Garratty, E. R. Stiehm, Y. J. Bryson, Y. Cao, J. P. Moore, D. D. Ho, and C. F. Barbas III. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027.
7. Cecilia, D., V. N. KewalRamani, J. O'Leary, B. Volsky, P. Nyambi, S. Burda, S. Xu, D. R. Littman, and S. Zolla-Pazner. 1998. Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J. Virol. 72:6988-6996.
8. Cheingsong-Popov, R., D. Callow, S. Beddows, S. Shaunak, C. Wasi, P. Kaleebu, C. Gilks, I. V. Petrascu, M. M. Garaev, D. M. Watts, N. T. Constantine, and J. N. Weber. 1992. Geographic diversity of human immunodeficiency virus type 1: serologic reactivity to Env epitopes and relationship to neutralization. J. Infect. Dis. 165:256-261.
9. Conley, A. J., M. K. Gorny, J. A. Kessler II, L. J. Boots, D. Lineberger, E. A. Emini, M. Ossorio, S. Koenig, C. Williams, and S. Zolla-Pazner. 1994. Neutralization of primary HIV-1 virus isolates by the broadly-reactive anti-V3 monoclonal antibody, 447-52D. J. Virol. 68:6994-7000.
10. Conley, A. J., J. A. Kessler, L. J. Boots, J.-S. Tung, B. A. Arnold, P. M. Keller, A. R. Shaw, and E. A. Emini. 1994. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc. Natl. Acad. Sci. USA 91: 3348-3352.
11. Davies, D. Personal communication.
12. Expert Group of the Joint United Nations Programme On HIV/AIDS. 1997. HIV-1 subtypes for epidemiology, pathogenicity, vaccines, and diagnostics. AIDS 11:17-36.
13. Ferrari, G., W. Humphrey, M. J. McElrath, J. L. Excler, A. M. Duliege, M. L. Clements, L. C. Corey, D. P. Bolognesi, and K. J. Weinhold. 1997. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc. Natl. Acad. Sci. USA 94:1396-1401.
14. Fouts, T. R., J. M. Binley, A. Trkola, J. E. Robinson, and J. P. Moore. 1997. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J. Virol. 71:2779-2785.
15. Gorny, M. K., A. J. Conley, S. Karwowska, A. Buchbinder, J.-Y. Xu, E. A. Emini, S. Koenig, and S. Zolla-Pazner. 1992. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J. Virol. 66:7538-7542.
16. Gorny, M. K., V. Gianakakos, S. Sharpe, and S. Zolla-Pazner. 1989. Generation of human monoclonal antibodies to HIV. Proc. Natl. Acad. Sci. USA 86:1624-1628.
17. Gorny, M. K., J. R. Mascola, Z. R. Israel, T. C. VanCott, C. Williams, P. Balfe, C. Hioe, S. Brodine, S. Burda, and S. Zolla-Pazner. 1998. A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades. AIDS Res. Hum. Retroviruses 14:213-221.
18. Gorny, M. K., T. C. VanCott, C. Hioe, Z. R. Israel, N. L. Michael, A. J. Conley, C. Williams, J. A. Kessler II, P. Chigurupati, S. Burda, and S. Zolla-Pazner. 1997. Human monoclonal antibodies to the V3 loop of HIV-1 with intra-and inter-clade cross-reactivity. J. Immunol. 159:5114-5122.
19. Gorny, M. K., T. C. VanCott, C. Williams, and S. Zolla-Pazner. Effects of oligomerization on the epitopes of HIV-1 envelope glycoproteins. Submitted for publication.
20. Gorny, M. K., J.-Y. Xu, V. Gianakakos, S. Karwowska, C. Williams, H. W. Sheppard, C. V. Hanson, and S. Zolla-Pazner. 1991. Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the HIV-1 envelope glycoprotein. Proc. Natl. Acad. Sci. USA 88:3238-3242.
21. Gorny, M. K., J.-Y. Xu, S. Karwowska, A. Buchbinder, and S. Zolla-Pazner. 1993. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J. Immunol. 150:635-643.
22. Goudsmit, J., C. Debouck, R. H. Meloen, L. Smit, M. Bakker, D. M. Asher, A. V. Wolff, C. J. Gibbs, Jr., and D. Carleton Gajdusek. 1988. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc. Natl. Acad. Sci. USA 85:4478-4482.
23. Hartigan, J. 1975. Clustering algorithms. J. Wiley and Sons, New York, N.Y.
24. Hioe, C. E., S. Xu, P. Chigurupati, S. Burda, C. Williams, M. K. Gorny, and S. Zolla-Pazner. 1997. Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. Int. Immunol. 9:1281-1290.
25. Janssens, W., L. Heyndrickx, K. Fransen, J. Mitte, M. Peeters, J. N. Nkengasong, P. M. Ndumbe, E. Delaporte, J.-L. Perret, C. Atende, P. Piot, and G. van der Groen. 1994. Genetic and phylogenetic analysis of env subtypes G and H in Central Africa. AIDS Res. Hum. Retroviruses 10:877-879.
26. Janssens, W., J. N. Nkengasong, L. Heyndrickx, K. Fransen, P. M. Ndumbe, E. Delaporte, M. Peeters, J.-L. Perret, A. Ndoumou, C. Atende, P. Piot, and G. van der Groen. 1994. Further evidence of the presence of genetically aberrant HIV-1 strains in Cameroon and Gabon. AIDS 8:1012-1013.
27. Keller, P. A., B. A. Arnold, A. R. Shaw, R. L. Tolman, F. V. Middlesworth, S. Bondy, V. K. Rosiecki, S. Koenig, S. Zolla-Pazner, P. Conrad, E. A. Emini, and A. J. Conley. 1992. Identification of HIV vaccine candidate peptides by screening random phage epitope libraries. Virology 169:893-897.
28. Kessler, J. A., II, P. M. McKenna, E. A. Emini, C. P. Chan, M. D. Patel, S. K. Gupta, G. E. Mark III, C. F. Barbas III, D. R. Burton, and A. J. Conley. 1997. Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates. AIDS Res. Hum. Retroviruses 13:575-582.
29. Korber, B. T. M., K. MacInnes, R. F. Smith, and G. Myers. 1994. Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1. J. Virol. 68:6730-6744.
30. Kostrikis, L. G., Y. Cao, H. Ngai, J. P. Moore, and D. D. Ho. 1996. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J. Virol. 70:445-458.
31. Kostrikis, L. G., E. Bagdades, Y. Cao, L. Zhang, D. Dimitriou, and D. D. Ho. 1995. Genetic analysis of human immunodeficiency virus type 1 strains from patients in Cyprus: identification of a new subtype designated subtype I. J. Virol. 69:6122-6130.
32. Lewi, P. J. 1976. Spectral mapping, a technique for classifying biological activity profiles of chemical compounds. Drug Res. 26:1295-1300.
33. Louwagie, J., F. E. McCutchan, M. Peeters, T. P. Brennan, E. Sanders-Buell, G. A. Eddy, G. van der Groen, K. Fransen, G.-M. Gershy-Damet, R. Deleys, and D. S. Burke. 1993. Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes. AIDS 7:769-780.
34. Mascola, J. R., J. Louwagie, F. E. McCutchan, C. L. Fischer, P. A. Hegerich, K. F. Wagner, A. K. Fowler, J. G. McNeil, and D. S. Burke. 1994. Two antigenically distinct subtypes of HIV-1: viral genotype predicts neutralization immunotype. J. Infect. Dis. 169:48-54.
35. Mauclere, P., F. Damond, C. Apetrel, I. Loussert-Ajaka, S. Souquiere, L. Buzelay, P. Dalbon, M. Jolivet, M. M. Lobe, F. Brun-Vezinet, F. Simon, and F. Barin. 1997. Synthetic peptide ELISAs for detection of and discrimination between group M and group O HIV type 1 infection. AIDS Res. Hum. Retroviruses 13:987-993.
36. Milligan, G. W., and M. C. Cooper. 1985 An examination of procedures for determining the number of clusters in a data set. Psychometrika 50:159-179.
37. Moore, J. P., Y. Cao, J. Leu, L. Qin, B. Korber, and D. D. Ho. 1996. Interand intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J. Virol. 70:427-444.
38. Moore, J. P., A. Trkola, B. Korber, L. J. Boots, J. A. Kessler II, F. E. McCutchan, J. Mascola, D. D. Ho, J. Robinson, and A. J. Conley. 1995. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. J. Virol. 69:122-130.
39. Morgado, M. G., E. C. Sabino, E. G. Shpaer, V. Bongertz, L. Brigido, M. D. C. Guimaraes, E. A. Castilho, B. Galvao-Castro, J. I. Mullins, R. M. Hendry, and A. Mayer. 1994. V3 region polymorphisms in HIV-1 from Brazil: prevalence of subtype B strains divergent from North American/ European prototype and detection of subtype F. AIDS Res. Hum. Retroviruses 10:569-576.
40. Myers, G., B. Korber, B. Foley, R. F. Smith, K.-T. Jeang, J. W. Mellors, and A. Wain-Hobson. 1996. Human retroviruses and AIDS. Theoretical Biology and Biophysics, Los Alamos National Laboratories, Los Alamos, N.Mex.
41. Myers, G., K. MacInnes, and B. Korber. 1992. The emergence of simian/ human immunodeficiency viruses. AIDS Res. Hum. Rctroviruses 8:373-386.
42. Myers, G., and G. N. Pavlakis. 1992. Evolutionary potential of complex retroviruses, p. 51-104. In J. A. Levy (ed.), The retroviruses. Plenum Press, New York, N.Y.
43. Nkengasong, J. N., W. Janssens, L. Heyndrickx, K. Fransen, P. M. Ndumbe, J. Motte, A. Leonaers, M. Ngolle, J. Ayuk, P. Piot, and G. van der Groen. 1994. Genetic subtypes of HIV-1 in Cameroon. AIDS 8:1405-1412.
44. Nyambi, P. N., M. K. Gorny, L. Bastiani, G. van der Groen, C. Williams, and S. Zolla-Pazner. 1998. Mapping of epitopes exposed on intact HIV-1 virions: a new strategy for studying the immunologic relatedness of HIV-1. J. Virol. 72:9384-9391.
45. Nyambi, P. N., J. Nkengasong, P. Lewi, K. Andries, W. Janssens, K. Fransen, L. Heyndrickx, P. Piot, and G. van der Groen. 1996. Multivariate analysis of human immunodeficiency virus type 1 neutralization data. J. Virol. 70:6235-6243.
46. Nyambi, P. N., J. Nkengasong, M. Peeters, F. Simon, J. Eberle, W. Janssens, K. Fransen, B. Willems, K. Vereecken, L. Heyndrickx, P. Piot, and G. van der Groen. 1995. Reduced capacity of antibodies from patients infected with human immunodeficiency virus type-1 (HIV-1) group O to neutralize primary isolates of HIV-1 group M viruses. J. Infect. Dis. 172:1228-1237.
47. Palker, T. J., M. E. Clark, A. L. Langlois, T. J. Matthews, K. J. Weinhold, R. R. Randall, D. P. Bolognesi, and G. Haynes. 1988. Type-specific neutralization of HIV with antibodies to env-encoded synthetic peptides. Proc. Natl. Acad. Sci. USA 85:1758-1762.
48. Plantier, J.-C., S. Le Pogam, F. Poisson, L. Buzelay, B. Lejeune, and F. Barin. 1998. Extent of antigenic diversity in the V3 region of the surface glycoprotein, gp120, of human immunodeficiency virus type 1 group M and consequences for serotyping. J. Virol. 72:677-683.
49. Starcich, B. R., B. H. Hahn, G. M. Shaw, P. D. McNeely, S. Modrow, H. Wolf, E. S. Parks, W. P. Parks, S. F. Josephs, R. C. Gallo, and F. Wong-Staal. 1986. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell 45:637-648.
50. Trkola, A., A. B. Pomales, H. Yuan, B. Korber, P. J. Maddon, G. P. Allaway. H. Katinger, C. F. Barbas III, D. R. Burton, D. D. Ho, and J. P. Moore. 1995 Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69:6609-6617.
51. Trkola, A., M. Purtscher, T. Muster, C. Ballaun, A. Buchacher, N. Sullivan, K. Srinivasan, J. Sodroski, J. P. Moore, and H. Katinger. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70: 1100-1108.
52. VanCott, T. C., F. R. Bethke, D. S. Burke, R. R. Redfield, and D. L. Birx. 1995. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J. Immunol. 155:4100-4110.
53. VanCott, T. C., S. C. D. Veit, V. Kalyanaraman, P. Earl, and D. L. Birx. 1995. Characterization of a soluble oligomeric HIV-1 gp160 protein as a potential immunogen. J. Immunol. Methods 183:103-117.
54. Weber, J., E.-M. Fenyö, S. Beddows, P. Kaleebu, Å. Björndal, and the WHO Network for HIV Isolation and Characterization. 1996. Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. J. Virol. 70:7827-7832.
55. Wolfs, T. F. W., G. Szart, M. Bakker, M. Valk, C. L. Kuiken, and J. Goudsmit. 1992. Naturally occurring mutations within HIV-1 V3 genomic RNA lead to antigenic variation dependent on a single amino acid substitution. Virology 185:195-205.
56. Zolla-Pazner, S., J. O'Leary, S. Burda, M. K. Gorny, M. Kim, J. Mascola, and F. McCutchan. 1995. Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry. J. Virol. 69:3807-3815.